Antitumor efficacy of a-solanine against pancreatic cancer pancreatic cancer in vitro and in vivo

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Lv, Chongqing ^a   Kong, Hongru ^a   Dong, Guohua ^a   Liu, Lewei ^a   Tong, Kun ^a   Sun, Hongwei ^a   Chen, Bicheng ^a   Zhang, Chunwu ^a   Zhou, Mengtao ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SOLANINE; ANTINEOPLASTIC AGENT; BETA CATENIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EXTRACELLULAR INDUCER OF MATRIX METALLOPROTEINASE; GELATINASE A; GELATINASE B; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MATRIX METALLOPROTEINASE; PROTEIN KINASE B; STAT3 PROTEIN; TRANSCRIPTION FACTOR 7; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN; ALPHA-SOLANINE; SOLANINE; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MIGRATION INHIBITION; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR VOLUME; ANIMAL; APOPTOSIS; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; METABOLISM; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; SOLANINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84895555442     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087868     Document Type: Article

References (45)

1. Bosetti C, Bertuccio P, Negri E, La Vecchia C, Zeegers MP, et al. (2012) Pancreatic cancer: overview of descriptive epidemiology. Mol Carcinog 51: 3-13.
2. Ducreux M, Boige V, Goere D, Deutsch E, Ezra P, et al. (2007) The multidisciplinary management of gastrointestinal cancer. Pancreatic cancer: from pathogenesis to cure. Best Pract Res Clin Gastroenterol 21: 997-1014.
3. Ksiazkiewicz M, Markiewicz A, Zaczek AJ (2012) Epithelial-mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells. Pathobiology 79: 195-208.
4. Gateley K (1990) Communicable disease reporting: why? J Tenn Med Assoc 83: 512-513.
5. Itoh Y, Nagase H (2002) Matrix metalloproteinases in cancer. Essays Biochem 38: 21-36. (Pubitemid 36589192)
6. Buda A, Pignatelli M (2011) E-cadherin and the cytoskeletal network in colorectal cancer development and metastasis. Cell Commun Adhes 18: 133-143.
7. Gao L, Antic T, Hyjek E, Gong C, Mueller J, et al. (2013) Immunohistochemical analysis of E-cadherin and zeste homolog 2 expression in endoscopic ultrasound-guided fine-needle aspiration of pancreatic adenocarcinoma. Cancer Cytopathol.
8. Chen S, Guttridge DC, You Z, Zhang Z, Fribley A, et al. (2001) Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. J Cell Biol 152: 87-96. (Pubitemid 32102439)
9. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, et al. (2010) Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 28: 245-255.
10. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, et al. (2011) DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331: 1199-1203.
11. Kim D, Kim S, Koh H, Yoon SO, Chung AS, et al. (2001) Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J 15: 1953-1962. (Pubitemid 32848799)
12. Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, et al. (2007) Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer 121: 1424-1432. (Pubitemid 47328700)
13. Mendoza MC, Er EE, Blenis J (2011) The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 36: 320-328.
14. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562.
15. Watson CJ, Miller WR (1995) Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br J Cancer 71: 840-844.
16. Gouilleux-Gruart V, Gouilleux F, Desaint C, Claisse JF, Capiod JC, et al. (1996) STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 87: 1692-1697. (Pubitemid 26068885)
17. Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, et al. (1995) Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269: 81-83.
18. Danial NN, Pernis A, Rothman PB (1995) Jak-STAT signaling induced by the vabl oncogene. Science 269: 1875-1877.
19. Kim J, Chang W, Jung Y, Song K, Lee I (2012) Wnt5a activates THP-1 monocytic cells via a beta-catenin-independent pathway involving JNK and NFkappaB activation. Cytokine 60: 242-248.
20. Guo C, Gasparian AV, Zhuang Z, Bosykh DA, Komar AA, et al. (2009) 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NFkappaB and p53 pathways. Oncogene 28: 1151-1161.
21. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, et al. (2007) Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67: 3853-3861. (Pubitemid 46762173)
22. Lee KR, Kozukue N, Han JS, Park JH, Chang EY, et al. (2004) Glycoalkaloids and metabolites inhibit the growth of human colon (HT29) and liver (HepG2) cancer cells. J Agric Food Chem 52: 2832-2839.
23. Yang SA, Paek SH, Kozukue N, Lee KR, Kim JA (2006) Alpha-chaconine, a potato glycoalkaloid, induces apoptosis of HT-29 human colon cancer cells through caspase-3 activation and inhibition of ERK 1/2 phosphorylation. Food Chem Toxicol 44: 839-846.
24. Kenny OM, McCarthy CM, Brunton NP, Hossain MB, Rai DK, et al. (2013) Anti-inflammatory properties of potato glycoalkaloids in stimulated Jurkat and Raw 264.7 mouse macrophages. Life Sci 92: 775-782.
25. Mohsenikia M, Alizadeh AM, Khodayari S, Khodayari H, Kouhpayeh SA, et al. (2013) The protective and therapeutic effects of alpha-solanine on mice breast cancer. Eur J Pharmacol 718: 1-9.
26. Yamashoji S, Matsuda T (2013) Synergistic cytotoxicity induced by alpha-solanine and alpha-chaconine. Food Chem 141: 669-674.
27. Wang S, Panter KE, Gaffield W, Evans RC, Bunch TD (2005) Effects of steroidal glycoalkaloids from potatoes (Solanum tuberosum) on in vitro bovine embryo development. Anim Reprod Sci 85: 243-250. (Pubitemid 39568959)
28. Blankemeyer JT, McWilliams ML, Rayburn JR, Weissenberg M, Friedman M (1998) Developmental toxicology of solamargine and solasonine glycoalkaloids in frog embryos. Food Chem Toxicol 36: 383-389. (Pubitemid 28267367)
29. Kang H, Jeong HD, Choi HY (2011) The chloroform fraction of Solanum nigrum suppresses nitric oxide and tumor necrosis factor-alpha in LPS-stimulated mouse peritoneal macrophages through inhibition of p38, JNK and ERK1/2. Am J Chin Med 39: 1261-1273.
30. Ding X, Zhu F, Yang Y, Li M (2013) Purification, antitumor activity in vitro of steroidal glycoalkaloids from black nightshade (Solanum nigrum L.). Food Chem 141: 1181-1186.
31. Gupta GP, Massague J (2006) Cancer metastasis: building a framework. Cell 127: 679-695. (Pubitemid 44781029)
32. Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572. (Pubitemid 37328923)
33. Fidler IJ (2003) The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458.
34. Bogenrieder T, Herlyn M (2003) Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22: 6524-6536. (Pubitemid 37372332)
35. Smigielski J, Piskorz L, Wojnarowska RT, Malecka-Panas E, Jablonski S, et al. (2013) The estimation of metaloproteinases and their inhibitors blood levels in patients with pancreatic tumors. World J Surg Oncol 11: 137.
36. Zhao M, Tang SN, Marsh JL, Shankar S, Srivastava RK (2013) Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice. Cancer Lett 337: 210-217.
37. Yamamoto T, Matsuda Y, Kawahara K, Ishiwata T, Naito Z (2012) Secreted 70kDa lumican stimulates growth and inhibits invasion of human pancreatic cancer. Cancer Lett 320: 31-39.
38. Riethdorf S, Reimers N, Assmann V, Kornfeld JW, Terracciano L, et al. (2006) High incidence of EMMPRIN expression in human tumors. Int J Cancer 119: 1800-1810. (Pubitemid 44356836)
39. Kim H, Zhai G, Samuel SL, Rigell CJ, Umphrey HR, et al. (2012) Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma. Mol Cancer Ther 11: 405-415.
40. Ohara Y, Oda T, Sugano M, Hashimoto S, Enomoto T, et al. (2013) Histological and prognostic importance of CD44/CD24/EpCAM expression in clinical pancreatic cancer. Cancer Sci.
41. Grothey A, Galanis E (2009) Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 6: 507-518.
42. Singh RP, Gu M, Agarwal R (2008) Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res 68: 2043-2050.
43. Nambiar D, Prajapati V, Agarwal R, Singh RP (2012) In vitro and in vivo anticancer efficacy of silibinin against human pancreatic cancer BxPC-3 and PANC-1 cells. Cancer Lett.
44. Naryzhny SN (2008) Proliferating cell nuclear antigen: a proteomics view. Cell Mol Life Sci 65: 3789-3808.
45. Ceballos MP, Parody JP, Alvarez Mde L, Ingaramo PI, Carnovale CE, et al. (2011) Interferon-alpha2b and transforming growth factor-beta1 treatments on HCC cell lines: Are Wnt/beta-catenin pathway and Smads signaling connected in hepatocellular carcinoma? Biochem Pharmacol 82: 1682-1691.